Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	cytoskeletal protein binding	EZR GRIA2 GC VPS16 PTPRT PXK MSN CCDC66 BRCA1 BRCA2 VILL SYNE2 KIF19 CLTC UNC13A RAB27A RAB27B FRMD3	7.86e-05	1099	118	18	GO:0008092
GeneOntologyBiologicalProcess	positive regulation of early endosome to late endosome transport	EZR PTPN23 MSN	1.46e-05	9	117	3	GO:2000643
GeneOntologyCellularComponent	photoreceptor cell cilium	CIB2 PDE6A CCDC66 IFT52 SHANK2 PCDH15 RAB27A	1.41e-05	139	118	7	GO:0097733
GeneOntologyCellularComponent	9+0 non-motile cilium	CIB2 PDE6A CCDC66 IFT52 SHANK2 PCDH15 RAB27A	2.62e-05	153	118	7	GO:0097731
GeneOntologyCellularComponent	photoreceptor outer segment	CIB2 PDE6A CCDC66 SHANK2 PCDH15 RAB27A	3.98e-05	111	118	6	GO:0001750
GeneOntologyCellularComponent	non-motile cilium	CIB2 PDE6A CCDC66 IFT52 SHANK2 PCDH15 RAB27A	1.25e-04	196	118	7	GO:0097730
GeneOntologyCellularComponent	Golgi-associated vesicle	PCLO SPPL3 CLTC UNC13A RAB27B	4.73e-04	114	118	5	GO:0005798
GeneOntologyCellularComponent	cilium	EZR CIB2 PDE6A PTPN23 PTCH1 USP26 FSIP2 CFAP54 CCDC66 IFT52 SHANK2 KIF19 PCDH15 RAB27A	5.42e-04	898	118	14	GO:0005929
MousePheno	postnatal lethality, complete penetrance	EZR FRAS1 APAF1 SPPL3 GRIA2 PTCH1 EDNRB CYFIP2 EFNB2 SLCO2A1 KIT UNC13A MMUT	1.85e-05	445	101	13	MP:0011085
Domain	B12-binding	MTR MMUT	3.56e-05	2	112	2	PF02310
Domain	Cobalamin-bd	MTR MMUT	3.56e-05	2	112	2	IPR006158
Domain	B12_BINDING	MTR MMUT	3.56e-05	2	112	2	PS51332
Domain	-	MTR MMUT	3.56e-05	2	112	2	3.40.50.280
Domain	FERM_N	EZR FRMPD1 MSN FRMD3	4.38e-05	33	112	4	IPR018979
Domain	FERM_N	EZR FRMPD1 MSN FRMD3	4.38e-05	33	112	4	PF09379
Domain	FERM_M	EZR FRMPD1 MSN FRMD3	1.65e-04	46	112	4	PF00373
Domain	-	EZR FRMPD1 MSN FRMD3	2.11e-04	49	112	4	1.20.80.10
Domain	FERM_central	EZR FRMPD1 MSN FRMD3	2.11e-04	49	112	4	IPR019748
Domain	FERM_domain	EZR FRMPD1 MSN FRMD3	2.11e-04	49	112	4	IPR000299
Domain	ERM_C_dom	EZR MSN	2.12e-04	4	112	2	IPR011259
Domain	ERM	EZR MSN	2.12e-04	4	112	2	PF00769
Domain	ERM	EZR MSN	2.12e-04	4	112	2	IPR011174
Domain	FERM/acyl-CoA-bd_prot_3-hlx	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	IPR014352
Domain	FERM_1	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	PS00660
Domain	FERM_2	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	PS00661
Domain	FERM_3	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	PS50057
Domain	Band_41_domain	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	IPR019749
Domain	B41	EZR FRMPD1 MSN FRMD3	2.28e-04	50	112	4	SM00295
Domain	Ez/rad/moesin-like	EZR MSN FRMD3	2.58e-04	21	112	3	IPR000798
Domain	ZINC_PROTEASE	PHEX LNPEP ADAMTS15 MMP2 ECE2	3.09e-04	98	112	5	PS00142
Domain	PolyA	PABPC4 PABPC1	3.52e-04	5	112	2	SM00517
Domain	HAT_MYST-type	KAT5 KAT7	3.52e-04	5	112	2	IPR002717
Domain	-	PABPC4 PABPC1	3.52e-04	5	112	2	1.10.1900.10
Domain	PABP	PABPC4 PABPC1	3.52e-04	5	112	2	PF00658
Domain	PABP_1234	PABPC4 PABPC1	3.52e-04	5	112	2	IPR006515
Domain	MOZ_SAS	KAT5 KAT7	3.52e-04	5	112	2	PF01853
Domain	PABC	PABPC4 PABPC1	3.52e-04	5	112	2	PS51309
Domain	PABP_HYD	PABPC4 PABPC1	3.52e-04	5	112	2	IPR002004
Domain	MYST_HAT	KAT5 KAT7	3.52e-04	5	112	2	PS51726
Domain	FERM_CS	EZR MSN FRMD3	3.88e-04	24	112	3	IPR019747
Domain	FERM_C	EZR MSN FRMD3	4.94e-04	26	112	3	PF09380
Domain	FERM_PH-like_C	EZR MSN FRMD3	5.53e-04	27	112	3	IPR018980
Domain	FERM_C	EZR MSN FRMD3	5.53e-04	27	112	3	SM01196
Domain	Peptidase_M13_C	PHEX ECE2	7.34e-04	7	112	2	IPR018497
Domain	Peptidase_M13	PHEX ECE2	7.34e-04	7	112	2	IPR000718
Domain	Peptidase_M13_N	PHEX ECE2	7.34e-04	7	112	2	PF05649
Domain	Peptidase_M13_N	PHEX ECE2	7.34e-04	7	112	2	IPR008753
Domain	Moesin_tail	EZR MSN	7.34e-04	7	112	2	IPR008954
Domain	Peptidase_M13	PHEX ECE2	7.34e-04	7	112	2	PF01431
Domain	VWFC_1	COL3A1 FRAS1 FSTL1	1.30e-03	36	112	3	PS01208
Domain	ANF_lig-bd_rcpt	NPR1 GRIA2 GRM5	1.41e-03	37	112	3	IPR001828
Domain	ANF_receptor	NPR1 GRIA2 GRM5	1.41e-03	37	112	3	PF01094
Domain	-	PHEX ADAMTS15 MMP2 ECE2	1.43e-03	81	112	4	3.40.390.10
Domain	MetalloPept_cat_dom	PHEX ADAMTS15 MMP2 ECE2	1.43e-03	81	112	4	IPR024079
Domain	VWFC_2	COL3A1 FRAS1 FSTL1	1.52e-03	38	112	3	PS50184
Domain	Peripla_BP_I	NPR1 GRIA2 GRM5	1.64e-03	39	112	3	IPR028082
Domain	VWF_dom	COL3A1 FRAS1 FSTL1	2.03e-03	42	112	3	IPR001007
Pathway	REACTOME_SENSORY_PROCESSING_OF_SOUND	EZR CIB2 CHRNA9 PCLO MSN PCDH15	1.37e-05	77	96	6	M41822
Pathway	REACTOME_SENSORY_PROCESSING_OF_SOUND_BY_OUTER_HAIR_CELLS_OF_THE_COCHLEA	EZR CIB2 CHRNA9 MSN PCDH15	3.50e-05	55	96	5	M41823
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	EZR PDS5B CIB2 PDE6A PCLO PABPC4 GRIA2 APOB PFKP ATP5MK PABPC1 CYFIP2 MSN PHEX ZC3H7A ERLIN2 SHANK2 BRCA1 SYNE2 CLTC ATG4C	1.93e-08	1442	119	21	35575683
Pubmed	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.	BRCA1 BRCA2 MTR	1.56e-07	4	119	3	17151928
Pubmed	Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.	BRCA1 BRCA2 MTR	3.89e-07	5	119	3	18842997
Pubmed	A novel role for BRCA1 in regulating breast cancer cell spreading and motility.	EZR MSN BRCA1	3.89e-07	5	119	3	21282464
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	EZR GRIA2 GRM5 VIRMA PABPC1 CYFIP2 MSN ZNF462 SHANK2 G3BP1 RABEP1 SYNE2 CLTC UNC13A PHLDB2	1.10e-06	963	119	15	28671696
Pubmed	Large-scale phage-based screening reveals extensive pan-viral mimicry of host short linear motifs.	PABPC1 G3BP1 RABEP1 CLTC	1.31e-06	24	119	4	37100772
Pubmed	Genetic susceptibility to distinct bladder cancer subphenotypes.	EZR NAT2 APAF1 TP53I3 GC APOB BRCA1 BRCA2 MTR NPAT	2.00e-06	421	119	10	19692168
Pubmed	Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.	NAT2 DPYD APOB BRCA1 BRCA2 KIT	2.03e-06	108	119	6	19956635
Pubmed	Genetic mutations associated with cigarette smoking in pancreatic cancer.	PTCH1 PTPRT BRCA1 BRCA2 KIT	2.58e-06	63	119	5	19351817
Pubmed	Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.	DPYD MTR UMPS	3.23e-06	9	119	3	20647221
Pubmed	Finding the Unicorn, a New Mouse Model of Midfacial Clefting.	EZR PTCH1 MSN	3.23e-06	9	119	3	31940751
Pubmed	A Large-scale genetic association study of esophageal adenocarcinoma risk.	NAT2 DPYD APAF1 TP53I3 BRCA1 BRCA2 MTR UMPS MMP2	3.58e-06	351	119	9	20453000
Pubmed	Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.	LZTR1 BRCA1 BRCA2	4.61e-06	10	119	3	37592023
Pubmed	DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2.	EZR PABPC4 PFKP PABPC1 CLTC	5.37e-06	73	119	5	35973989
Pubmed	Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent.	USP26 BRCA2 MTR KIT	1.08e-05	40	119	4	20378615
Pubmed	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	BRCA1 BRCA2	1.16e-05	2	119	2	17924331
Pubmed	Oral contraceptive use and BRCA penetrance: a case-only study.	BRCA1 BRCA2	1.16e-05	2	119	2	19549808
Pubmed	Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.	BRCA1 BRCA2	1.16e-05	2	119	2	34101484
Pubmed	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.	BRCA1 BRCA2	1.16e-05	2	119	2	20512419
Pubmed	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.	BRCA1 BRCA2	1.16e-05	2	119	2	22053997
Pubmed	Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.	BRCA1 BRCA2	1.16e-05	2	119	2	18200524
Pubmed	Fertility in women with BRCA mutations: a case-control study.	BRCA1 BRCA2	1.16e-05	2	119	2	19200971
Pubmed	Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.	BRCA1 BRCA2	1.16e-05	2	119	2	28212807
Pubmed	A role for Rab27 in neutrophil chemotaxis and lung recruitment.	RAB27A RAB27B	1.16e-05	2	119	2	25359237
Pubmed	Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	35980168
Pubmed	BRCA mutations and risk of prostate cancer in Ashkenazi Jews.	BRCA1 BRCA2	1.16e-05	2	119	2	15131025
Pubmed	BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.	BRCA1 BRCA2	1.16e-05	2	119	2	22425665
Pubmed	Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.	BRCA1 BRCA2	1.16e-05	2	119	2	22425664
Pubmed	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.	BRCA1 BRCA2	1.16e-05	2	119	2	22970155
Pubmed	Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.	BRCA1 BRCA2	1.16e-05	2	119	2	34304065
Pubmed	Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	26852015
Pubmed	Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.	BRCA1 BRCA2	1.16e-05	2	119	2	18175183
Pubmed	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	BRCA1 BRCA2	1.16e-05	2	119	2	23810788
Pubmed	Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.	BRCA1 BRCA2	1.16e-05	2	119	2	20972632
Pubmed	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	18165636
Pubmed	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.	BRCA1 BRCA2	1.16e-05	2	119	2	33558422
Pubmed	Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.	BRCA1 BRCA2	1.16e-05	2	119	2	33534430
Pubmed	BRCA 1, 2 mutation and earlier menopause: could BRCA 1,2 be used as predictor of menopause?	BRCA1 BRCA2	1.16e-05	2	119	2	34137566
Pubmed	BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.	BRCA1 BRCA2	1.16e-05	2	119	2	33918338
Pubmed	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	26181175
Pubmed	Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.	BRCA1 BRCA2	1.16e-05	2	119	2	14517958
Pubmed	Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	18559571
Pubmed	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.	BRCA1 BRCA2	1.16e-05	2	119	2	18559594
Pubmed	The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.	BRCA1 BRCA2	1.16e-05	2	119	2	11981002
Pubmed	Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.	BRCA1 BRCA2	1.16e-05	2	119	2	28199346
Pubmed	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.	BRCA1 BRCA2	1.16e-05	2	119	2	18092194
Pubmed	Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.	BRCA1 BRCA2	1.16e-05	2	119	2	31095775
Pubmed	A mitochondrial iron-responsive pathway regulated by DELE1.	DELE1 LONP1	1.16e-05	2	119	2	37327776
Pubmed	Screening for Genetic Testing in Breast Cancer - Are We Missing the Full Picture?	BRCA1 BRCA2	1.16e-05	2	119	2	26254840
Pubmed	Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.	BRCA1 BRCA2	1.16e-05	2	119	2	19491894
Pubmed	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	29116468
Pubmed	BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.	BRCA1 BRCA2	1.16e-05	2	119	2	26026974
Pubmed	[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people].	BRCA1 BRCA2	1.16e-05	2	119	2	15059511
Pubmed	BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.	BRCA1 BRCA2	1.16e-05	2	119	2	12112655
Pubmed	Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer?	BRCA1 BRCA2	1.16e-05	2	119	2	22339411
Pubmed	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.	BRCA1 BRCA2	1.16e-05	2	119	2	34906479
Pubmed	Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.	BRCA1 BRCA2	1.16e-05	2	119	2	12376518
Pubmed	Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers.	BRCA1 BRCA2	1.16e-05	2	119	2	32599251
Pubmed	BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.	BRCA1 BRCA2	1.16e-05	2	119	2	28549976
Pubmed	Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.	BRCA1 BRCA2	1.16e-05	2	119	2	28439188
Pubmed	Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.	BRCA1 BRCA2	1.16e-05	2	119	2	36156322
Pubmed	Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	25311111
Pubmed	Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.	BRCA1 BRCA2	1.16e-05	2	119	2	19875889
Pubmed	Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.	BRCA1 BRCA2	1.16e-05	2	119	2	28680148
Pubmed	Anticipation in hereditary breast cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	12220452
Pubmed	Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.	BRCA1 BRCA2	1.16e-05	2	119	2	25085752
Pubmed	BRCA mutation carriers do not have compromised ovarian reserve.	BRCA1 BRCA2	1.16e-05	2	119	2	24378620
Pubmed	Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.	BRCA1 BRCA2	1.16e-05	2	119	2	22972572
Pubmed	Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome.	LZTR1 SOS2	1.16e-05	2	119	2	25795793
Pubmed	Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.	BRCA1 BRCA2	1.16e-05	2	119	2	27793035
Pubmed	BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.	BRCA1 BRCA2	1.16e-05	2	119	2	19064968
Pubmed	[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].	BRCA1 BRCA2	1.16e-05	2	119	2	16324400
Pubmed	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	BRCA1 BRCA2	1.16e-05	2	119	2	14576434
Pubmed	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.	BRCA1 BRCA2	1.16e-05	2	119	2	28356425
Pubmed	[Molecular alterations in breast cancer: clinical implications and new analytical tools].	BRCA1 BRCA2	1.16e-05	2	119	2	15936476
Pubmed	Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.	BRCA1 BRCA2	1.16e-05	2	119	2	22736296
Pubmed	High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.	BRCA1 BRCA2	1.16e-05	2	119	2	27553291
Pubmed	The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	15131400
Pubmed	An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?	BRCA1 BRCA2	1.16e-05	2	119	2	15131403
Pubmed	BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.	BRCA1 BRCA2	1.16e-05	2	119	2	26335130
Pubmed	Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	36203093
Pubmed	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	BRCA1 BRCA2	1.16e-05	2	119	2	12677558
Pubmed	Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.	BRCA1 BRCA2	1.16e-05	2	119	2	17307836
Pubmed	Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	12100744
Pubmed	High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.	BRCA1 BRCA2	1.16e-05	2	119	2	17997147
Pubmed	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	BRCA1 BRCA2	1.16e-05	2	119	2	16912212
Pubmed	Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.	BRCA1 BRCA2	1.16e-05	2	119	2	19606050
Pubmed	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.	BRCA1 BRCA2	1.16e-05	2	119	2	32066851
Pubmed	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	25919761
Pubmed	BRCA mutations and reproduction.	BRCA1 BRCA2	1.16e-05	2	119	2	29307397
Pubmed	Improved survival in women with BRCA-associated ovarian carcinoma.	BRCA1 BRCA2	1.16e-05	2	119	2	12712470
Pubmed	Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.	BRCA1 BRCA2	1.16e-05	2	119	2	27283172
Pubmed	Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population.	BRCA1 BRCA2	1.16e-05	2	119	2	19669600
Pubmed	Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.	BRCA1 BRCA2	1.16e-05	2	119	2	20406939
Pubmed	Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.	BRCA1 BRCA2	1.16e-05	2	119	2	21898151
Pubmed	Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.	BRCA1 BRCA2	1.16e-05	2	119	2	26183948
Pubmed	Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.	BRCA1 BRCA2	1.16e-05	2	119	2	35217802
Pubmed	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.	BRCA1 BRCA2	1.16e-05	2	119	2	29309945
Pubmed	Molecular and in silico analysis of BRCA1 and BRCA2 variants.	BRCA1 BRCA2	1.16e-05	2	119	2	18694767
Pubmed	Body weight and risk of breast cancer in BRCA1/2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	20730487
Interaction	POLE interactions	PLBD1 CIB2 PABPC4 VIRMA PABPC1 ZBBX BRCA1 BRCA2	1.33e-06	139	115	8	int:POLE
Interaction	TNIK interactions	EZR GRIA2 GRM5 VIRMA CYFIP2 ZNF462 LONP1 SHANK2 G3BP1 SYNE2 OCLN UNC13A	1.88e-06	381	115	12	int:TNIK
Interaction	SYCP3 interactions	SPPL3 PABPC1 BRCA1 G3BP1	3.65e-06	19	115	4	int:SYCP3
Interaction	SPTAN1 interactions	EZR KAT5 ZFYVE16 GRIA2 FNDC3A APOB VIRMA CYFIP2 MSN BRCA1 SYNE2 CLTC OCLN	5.17e-06	496	115	13	int:SPTAN1
Interaction	GAPDH interactions	DPYD KAT5 PABPC4 FRMPD1 GRIA2 FNDC3A VIRMA PABPC1 MSN ERLIN2 BRCA1 G3BP1 TET1 CLTC NPAT	8.38e-06	686	115	15	int:GAPDH
Interaction	PALB2 interactions	PDS5B NAT2 SPPL3 VIRMA BRCA1 BRCA2	1.28e-05	90	115	6	int:PALB2
Interaction	IFITM1 interactions	ZFYVE16 PTPN23 APOB VPS16 PFKP LONP1 ERLIN2 LNPEP RABEP1 CLTC	3.67e-05	355	115	10	int:IFITM1
Interaction	SH3D19 interactions	EZR PTPN23 VIRMA OCLN SOS2	4.66e-05	69	115	5	int:SH3D19
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	EZR FRMPD1 MSN FRMD3	6.67e-05	50	79	4	1293
Coexpression	RODWELL_AGING_KIDNEY_NO_BLOOD_DN	PCLO DELE1 ERLIN2 SHANK2 MTR MMUT FRMD3 TPD52	3.47e-07	148	117	8	M11837
Coexpression	RODWELL_AGING_KIDNEY_DN	PCLO ERLIN2 SHANK2 MTR MMUT FRMD3 TPD52	4.69e-06	148	117	7	M5408
Coexpression	KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP	DPYD APAF1 BRCA1 MTR UMPS MMP2	1.53e-05	118	117	6	M12313
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBGABA	NOL4 PCLO GRIA2 PFKP GRM5 PTPRT PXK CYFIP2 ZNF248 ZNF462 SHANK2 UNC13A FRMD3	1.59e-05	703	117	13	M39070
Coexpression	KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP	DPYD APAF1 BRCA1 MTR UMPS MMP2	2.64e-05	130	117	6	M13537
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	NOL4 AFF2 PCLO GRIA2 PFKP GRM5 PTPRT PXK CYFIP2 ZNF248 ZNF462 FSIP2 FAT2 SHANK2 UNC13A FRMD3	3.33e-05	1106	117	16	M39071
Coexpression	STK33_SKM_DN	CYFIP2 SLC25A32 BMX MTR CARS2 KIT RAB27B TPD52	3.46e-05	276	117	8	M2856
Coexpression	STK33_NOMO_DN	IL18RAP CYFIP2 SLC25A32 BMX TET1 MTR CARS2 KIT	4.03e-05	282	117	8	M2854
Coexpression	CUI_DEVELOPING_HEART_C4_ENDOTHELIAL_CELL	NPR1 EDNRB MSN BMX EFNB2 SLCO2A1	5.07e-05	146	117	6	M39301
Coexpression	HU_FETAL_RETINA_FIBROBLAST	COL3A1 PLBD1 TP53I3 PTCH1 MSN EFNB2 FSTL1 MMP2 PHLDB2	5.93e-05	385	117	9	M39264
Coexpression	CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5	EZR PLBD1 CALML5 EFNB2 SHANK2 CLTC AACS OCLN RAB27B PHLDB2	7.24e-05	491	117	10	M13661
ToppCell	PCW_07-8.5-Epithelial-Epithelial_neuroendo-epi_NE_progenitor_(7)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	NOL4 FRAS1 PCLO CYFIP2 CFAP54 SHANK2 OCLN RAB27B FRMD3 TPD52	9.50e-11	192	117	10	b99f8236ef4ccdc75c02abea381cae6453205f6f
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX FSTL1 PCDH15 ADAMTS15 MMP2 FRMD3	5.97e-08	200	117	8	bd8cf33502adea320e91ca2af14e1911d88ad374
ToppCell	droplet-Lung-1m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PDS5B BMX ERLIN2 EFNB2 FSTL1 OCLN FRMD3	5.19e-07	181	117	7	136b0c60680068838d184d32aa99d7bea8718dbc
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D175\|Adult / Lineage, Cell type, age group and donor	IL18RAP EFNB2 ST8SIA6 SLCO2A1 PCDH15 KIT CCDC116	6.46e-07	187	117	7	f3548817f2fded5978137bb252cb628ac199e4f6
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FRAS1 PCLO SHANK2 OCLN RAB27B FRMD3 TPD52	6.94e-07	189	117	7	7659c7bbd58ee959a159294fb8d17317bbcc5681
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL3A1 PTCH1 PHEX FSTL1 PCDH15 MMP2 FRMD3	6.94e-07	189	117	7	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FRAS1 CFAP54 SHANK2 OCLN RAB27B FRMD3 TPD52	8.26e-07	194	117	7	f95c8dc242c9aebcadfe61b1ed033349cb7e5a88
ToppCell	COVID-19_Severe-Lymphoid_T/NK-gd_T\|COVID-19_Severe / Disease group, lineage and cell class	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	8.55e-07	195	117	7	9990440bda7fac5d00ef80444fab07459be625e1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	8.85e-07	196	117	7	418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	8.85e-07	196	117	7	581fc8c8d42005aacd7b401a2c9d1fc331fb4af7
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	8.85e-07	196	117	7	6beaf0c2799424c59819b286fbb5c1a83d85e4d1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	8.85e-07	196	117	7	c35f2349dfe35baa845f790b9f31673dceac54c0
ToppCell	356C-Fibroblasts-Fibroblast-F-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	COL3A1 PLBD1 TP53I3 LAMA2 CTSA FSTL1 MMP2	9.80e-07	199	117	7	beca4c7eb29ac771fd37f30cd23d4dce4afcfff8
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GRIA2 GRM5 PTPRT CYFIP2 ZNF462 KIF19 PCDH15	9.80e-07	199	117	7	333056c2abe9724efeab542c0365fcfe4eff8f18
ToppCell	356C-Fibroblasts-Fibroblast-F\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	COL3A1 PLBD1 TP53I3 LAMA2 CTSA FSTL1 MMP2	9.80e-07	199	117	7	cd3ab9a75b40e0d417d53b3d8756fc9bed30ac83
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GRIA2 GRM5 PTPRT CYFIP2 ZNF462 KIF19 PCDH15	9.80e-07	199	117	7	19a97e27a4758e794ce7246d295e112b47931a48
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GRIA2 GRM5 PTPRT CYFIP2 ZNF462 KIF19 PCDH15	9.80e-07	199	117	7	e60ecbb8fa7bcd3e2ce7d78f6efb2cfd1fd77698
ToppCell	Control_saline-Mesenchymal_fibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX PCDH15 ADAMTS15 MMP2 FRMD3	1.01e-06	200	117	7	64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	COL3A1 FRAS1 LAMA2 PHEX FSTL1 PCDH15 MMP2	1.01e-06	200	117	7	aa1a35dcca3b799241eef4237f6eb94660e019f0
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	COL3A1 FRAS1 LAMA2 PHEX FSTL1 PCDH15 MMP2	1.01e-06	200	117	7	a510deaada669e690329183e18df02870bd204b3
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated\|COVID-19_Mild / Disease, condition lineage and cell class	PTCH1 IL18RAP CYFIP2 MSN LNPEP SYNE2 PHLDB2	1.01e-06	200	117	7	2281debd86e5d92e8fe0397aec9ef670800f7471
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts\|Control_saline / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX PCDH15 ADAMTS15 MMP2 FRMD3	1.01e-06	200	117	7	a1fc74c1b27e104895910bc7cdce7ba33d30df7e
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-gd_T\|COVID-19_Severe / Disease, condition lineage and cell class	RBL2 LAMA2 PTCH1 IL18RAP CYFIP2 LNPEP SYNE2	1.01e-06	200	117	7	f72bc3f6606ae77fe1b0a972e35b3ce0727804d9
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL3A1 FRAS1 LAMA2 PHEX FSTL1 PCDH15 MMP2	1.01e-06	200	117	7	dd4228cbed8a4395166a6332e08d44d88bebe3b9
ToppCell	Severe-Myeloid-Mast-\|Severe / Condition, Lineage, Cell class and cell subclass	PDE6A AFF2 ZNF462 ST8SIA6 KIT RAB27B	2.35e-06	145	117	6	ce307d45425a5191882078f049f85477eec40b69
ToppCell	Severe-Myeloid-Mast\|Severe / Condition, Lineage, Cell class and cell subclass	PDE6A AFF2 ZNF462 ST8SIA6 KIT RAB27B	2.35e-06	145	117	6	e0bfd2ffdbd6c197ef0a04e983396ebd87ef7127
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CHRNA9 GRIA2 GRM5 PTPRT PCDH15 UNC13A	2.86e-06	150	117	6	0205318a870e091add66ee4305747dda9f51510d
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|kidney / Disease (COVID-19 only), tissue and cell type	PDE6A CHRNA9 GRIA2 PTPRT PCDH15 UNC13A	4.63e-06	163	117	6	19c28ce16a588a7f4a035c32726f6ccd67702b5b
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Epithelial-neuronal_stem_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GNPDA1 MATN1 BRCA1 KIF19 MANSC4 FRMD3	4.96e-06	165	117	6	1703d3eb644b3c743ad3c5532b1d29ea010c79c8
ToppCell	facs-Brain_Myeloid-Hippocampus-3m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL3A1 PLBD1 CYFIP2 BMX VILL SYNE2	6.51e-06	173	117	6	c63a615998d13b1725b5767f4ad2ec7e2b61db68
ToppCell	PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL3A1 PHEX BRCA1 BRCA2 MANSC4 MMP2	7.18e-06	176	117	6	cb8fd56a4f935cdda19d7ab43382cdda7c307667
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_D_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AFF2 GRIA2 GC PTPRT PER3 PCDH15	8.17e-06	180	117	6	8bf6e8b6b45ce42f8c5f23e7cd1752ec8b3fa2d2
ToppCell	-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	COL3A1 PDE6A FSTL1 ST8SIA6 ADAMTS15 KIT	8.43e-06	181	117	6	ef579e958f334da0f9415aa7e3d5c02c807954a6
ToppCell	facs-Skin-Anagen-3m-Epithelial-Basal_IFE\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PLBD1 PFKP SBNO2 SLCO2A1 RAB27A PHLDB2	8.70e-06	182	117	6	22d6f4790950508e8aa27e02a8133af5f53f13c8
ToppCell	facs-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	COL3A1 TSGA13 LAMA2 FSTL1 PCDH15 MMP2	1.05e-05	188	117	6	bba6b273bd47dd0e27fde914e9e6fc9d76fd5176
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EDNRB ZNF462 BMX OCLN RAB27A PHLDB2	1.08e-05	189	117	6	8e583ec4df0f5b79ce5211cc99ecd8616d180bde
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EDNRB ZNF462 BMX OCLN RAB27A PHLDB2	1.08e-05	189	117	6	fb2253b8463d08b3d28e952a31a23dea2c2d986b
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell-D175\|Adult / Lineage, Cell type, age group and donor	COL3A1 LAMA2 GRM5 FSTL1 ADAMTS15 PHLDB2	1.11e-05	190	117	6	7dcca3469f3a3b70db0420cb94f7765f39492f06
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_intermediate_(1)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FRAS1 PCLO CYFIP2 SHANK2 OCLN TPD52	1.11e-05	190	117	6	c95032bb3ee2b3d40fdf48016acb46d6f78a48a6
ToppCell	PND01-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	EDNRB BMX EFNB2 FSTL1 SLCO2A1 FRMD3	1.11e-05	190	117	6	eae5bcdb8a35f3fba4d25854c1a43f83f80832a2
ToppCell	PND01-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	EDNRB BMX EFNB2 FSTL1 SLCO2A1 FRMD3	1.11e-05	190	117	6	3346bfd0474828b3729cffa9f4cc57b04dd30443
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_secretory_(0)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FRAS1 CFAP54 SHANK2 OCLN RAB27B FRMD3	1.14e-05	191	117	6	60ff989fe99d243a3d52955223680cdd1f1917a4
ToppCell	droplet-Heart-HEART-1m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRMPD1 EDNRB BMX OCLN KIT RAB27A	1.14e-05	191	117	6	4bfdf44d4402a42530d30c89d94946acdda4321b
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FRAS1 AFF2 FRMPD1 PTPRT PCDH15 KIT	1.14e-05	191	117	6	7b386512284dfaa0e95358b28ee82632ee965e64
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FRAS1 FRMPD1 PTPRT PCDH15 KIT ECE2	1.14e-05	191	117	6	fa50a3c7ff86e1ee07100da1ace0b0fa1b0ab26b
ToppCell	COVID-19-Heart-EC_(POSTN)\|Heart / Disease (COVID-19 only), tissue and cell type	NPR1 BMX EFNB2 ST8SIA6 SLCO2A1 PCDH15	1.18e-05	192	117	6	c0c34785a7bdf461722029b322e9184e3d9b3c26
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)\|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PLBD1 AFF2 APAF1 TP53I3 BMX RAB27A	1.18e-05	192	117	6	072281344d58e85c9a290750b488d0c101f75d54
ToppCell	facs-Heart-LA-3m-Endothelial-endothelial_cell_of_endocardium\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EDNRB BMX EFNB2 SLCO2A1 OCLN RAB27A	1.18e-05	192	117	6	14a816ef116aa992f86edab411f043cf7d07fe04
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL3A1 PHEX FSTL1 PCDH15 MMP2 FRMD3	1.18e-05	192	117	6	f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b
ToppCell	facs-Heart-LA-3m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EDNRB BMX EFNB2 SLCO2A1 OCLN RAB27A	1.18e-05	192	117	6	847822514d747a21d5eb40e04ba9a023fd32bd65
ToppCell	PCW_05-06-Epithelial-Epithelial_neuroendo\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	NOL4 SHANK2 KIF19 OCLN FRMD3 TPD52	1.21e-05	193	117	6	aa10924b203c71e65fdbd2b90ba131dbd362d8b1
ToppCell	droplet-Fat-Scat-18m-Mesenchymal-Cd34+\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL3A1 LAMA2 FSTL1 SLCO2A1 ADAMTS15 MMP2	1.21e-05	193	117	6	316ebdf15f75d88c348f909b643fcd315364ca84
ToppCell	droplet-Heart-HEART-1m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EDNRB BMX SLCO2A1 OCLN KIT RAB27A	1.21e-05	193	117	6	d0a5f212f8e8a13dbbe3e41df92548ef82eef70b
ToppCell	droplet-Fat-Scat-18m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL3A1 LAMA2 FSTL1 SLCO2A1 ADAMTS15 MMP2	1.21e-05	193	117	6	1afdd3f7d703f4204a2cbfe40e135ac7b09213f7
ToppCell	PCW_13-14-Epithelial-Epithelial_neuroendo\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	NOL4 PCLO GRIA2 KIF19 UNC13A TPD52	1.21e-05	193	117	6	8603d1a38955ad2529d04e4704467c73ea5bfbda
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	BMX EFNB2 ST8SIA6 SLCO2A1 SYNE2 PCDH15	1.21e-05	193	117	6	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	droplet-Fat-Scat-18m-Mesenchymal\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL3A1 LAMA2 FSTL1 SLCO2A1 ADAMTS15 MMP2	1.21e-05	193	117	6	8dc6db335678f3a5cfd36026ad811fed8d9cb4bc
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	COL3A1 LAMA2 FSTL1 ADAMTS15 MMP2 PHLDB2	1.21e-05	193	117	6	261cafc167c86ab277be4ea7f08b0173e2dde26e
ToppCell	facs-Lung-nan-3m-Endothelial-endothelial_cell_of_lung\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NPR1 EFNB2 SLCO2A1 OCLN KIT PHLDB2	1.25e-05	194	117	6	f159ef8541d75a4e98468947f231bb463bec922c
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_2_(CH25H+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CIB2 PTCH1 EDNRB SHANK2 MMP2 RAB27B	1.25e-05	194	117	6	735eee6ef25589f935fa922788ebbdbfef61249e
ToppCell	droplet-Lung-LUNG-1m-Mesenchymal\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL3A1 LAMA2 FSTL1 PER3 ADAMTS15 MMP2	1.25e-05	194	117	6	d47e3c7b22444aef0c7a37bc8cd8853b590a56dd
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor2_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	CFAP54 SHANK2 OCLN RAB27B FRMD3 TPD52	1.25e-05	194	117	6	6b286992d4bb56013c0ea5a7601d3476d806175a
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL3A1 PHEX FSTL1 PCDH15 ADAMTS15 FRMD3	1.25e-05	194	117	6	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	Control-Classical_Monocyte-cMono_2\|Control / Disease condition and Cell class	PLBD1 DPYD ATP5MK CTSA MSN RAB27A	1.29e-05	195	117	6	0fea64ee3eedf3929abb0dd9c5f5fc72f181eed9
ToppCell	PCW_13-14-Epithelial-Epithelial_neuroendo-epi_neuroendocrine1[NE1]_(11)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	NOL4 PCLO GRIA2 KIF19 UNC13A TPD52	1.29e-05	195	117	6	5f33ece997f074598b4201ff74f592ee07c86a06
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL3A1 LAMA2 EDNRB FSTL1 ADAMTS15 MMP2	1.29e-05	195	117	6	2414b158dc7bdec43a9671544bfb7ffc5f5168fd
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	COL3A1 LAMA2 FSTL1 PCDH15 ADAMTS15 MMP2	1.33e-05	196	117	6	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	Bronchial-NucSeq-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-30 AFF2 FNDC3A CFAP54 TET1 TPD52	1.33e-05	196	117	6	fd18a9ae8401121ae276adff1a85d5f938e2df91
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal-mesenchymal-mesenchymal_stem_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL3A1 NPR1 LAMA2 EDNRB FSTL1 MMP2	1.36e-05	197	117	6	3bb92dd8a94e2be3b7fe51c9a21b241215477ac7
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL3A1 NPR1 LAMA2 EDNRB FSTL1 MMP2	1.36e-05	197	117	6	17344464fdcc5ba0c03959696b97c195f11e644c
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal-mesenchymal\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL3A1 NPR1 LAMA2 EDNRB FSTL1 MMP2	1.36e-05	197	117	6	5b8d0d7116b20d8e27541e88ec80c9f1f477e384
ToppCell	background-Hepatic_Stellate_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	COL3A1 LAMA2 GC EDNRB FSTL1 ADAMTS15	1.40e-05	198	117	6	79f32f965aed6a10c5cb803173e3db7b32e07a91
ToppCell	background-Hepatic_Stellate_cells\|background / Sample and Cell Type and Tumor Cluster (all cells)	COL3A1 LAMA2 EDNRB FSTL1 ADAMTS15 MMP2	1.40e-05	198	117	6	bd11b0e9e80449aab979a02c1023e0638c431c7c
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX FSTL1 ADAMTS15 MMP2	1.44e-05	199	117	6	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	LPS_anti-TNF-Epithelial_airway-airway_epithelial\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	EZR GC ZBBX CFAP54 VILL KIF19	1.44e-05	199	117	6	60919c2af31d39a2d36d7bc432e43dab2a4e05fb
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX FSTL1 ADAMTS15 MMP2	1.44e-05	199	117	6	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	COL3A1 PHEX FSTL1 PCDH15 MMP2 FRMD3	1.44e-05	199	117	6	8b86c69aaf60feff53aa782559cfece7342a23de
ToppCell	LPS_anti-TNF-Epithelial_airway\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	EZR GC ZBBX CFAP54 VILL KIF19	1.44e-05	199	117	6	6aca164bbbb961f34b1e6f1857f91ade5c059405
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL3A1 CIB2 PTCH1 MMP2 KIT RAB27B	1.44e-05	199	117	6	bdedcc7c8f3be0996200c882dda82fb2658655c0
ToppCell	3'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_1_(HAND1+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL3A1 ZNF462 EFNB2 SLCO2A1 KIT PHLDB2	1.44e-05	199	117	6	4217b9e66c5374461e84bdb893ab650f148286c8
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX FSTL1 ADAMTS15 MMP2	1.49e-05	200	117	6	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	COL3A1 FRAS1 LAMA2 PHEX FSTL1 MMP2	1.49e-05	200	117	6	8c62f05c6042f24287a73fbdf80ff4a56f7ff403
ToppCell	Transplant_Alveoli_and_parenchyma-Mesenchymal-Mesothelium\|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X	COL3A1 FRAS1 FSTL1 ADAMTS15 MMP2 PHLDB2	1.49e-05	200	117	6	c082bc21ec7c5323439d108ea8aea510e1113c3f
ToppCell	3'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL3A1 PTCH1 FSTL1 SYNE2 MMP2 RAB27B	1.49e-05	200	117	6	3dacd0afe69bc16bb33336ea9ea99a9cd47731d9
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	COL3A1 PTCH1 PHEX FSTL1 ADAMTS15 MMP2	1.49e-05	200	117	6	a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCell	Tracheal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	COL3A1 NPR1 LAMA2 APOB PXK MMP2	1.49e-05	200	117	6	3e0041c04e42a47257517dae8707a6454570c256
ToppCell	severe-immature_Neutrophil\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	PLBD1 AFF2 APAF1 BMX BRCA2 RAB27A	1.49e-05	200	117	6	a9b87accdaa6956116ab82427e1330e8f007ef94
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_granulocytic-neutrophil\|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PLBD1 APAF1 IL18RAP BMX RAB27A SOS2	1.49e-05	200	117	6	808571d74bb5c4d765ff13fc9393f88020d4e90d
ToppCell	LPS-IL1RA-Endothelial-Epi-like-Alv_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NPR1 PTPN23 EDNRB KIT RAB27B	3.21e-05	138	117	5	5f8ac8f67e34a7cf560099208e6884102532391e
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P1-Tnr-Polydendrocyte.Tnr.Pdgfa-Pik3r3_(Pdgfa)\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	MATN1 BRCA1 KIF19 MANSC4	3.69e-05	71	117	4	2220e1b02baa71961cfc85536bafeb313e588bf3
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P1-Tnr-Polydendrocyte.Tnr.Pdgfa-Pik3r3_(Pdgfa)-\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	MATN1 BRCA1 KIF19 MANSC4	3.69e-05	71	117	4	cc5de8bbcfefa2bf93cc137c74b49a745d5da229
ToppCell	PND01-Immune-Immune_Myeloid-Granulocytic-Neutrophil\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PLBD1 IL18RAP CYFIP2 BMX TPD52	4.63e-05	149	117	5	4de52569611e63a780cde9bd111d6d9c11a05a11
ToppCell	PND01-Immune-Immune_Myeloid-Granulocytic-Neutrophil-Neutrophil_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PLBD1 IL18RAP CYFIP2 BMX TPD52	4.63e-05	149	117	5	c957ac23ad6343eacce7e6be4a6d3ac043af4f86
ToppCell	primary_visual_cortex-Non-neuronal-pericyte_cell-Peri-Peri_Kcnj8\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CYSLTR2 LAMA2 NR1H3 MSN PHLDB2	5.59e-05	155	117	5	ced64e26962c5c6e6d539f361fe57ab0b399e999
ToppCell	primary_visual_cortex-Non-neuronal-pericyte_cell\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CYSLTR2 LAMA2 NR1H3 MSN PHLDB2	5.59e-05	155	117	5	0f24ef6486aef354f0911c06932cb01d1a0525ac
ToppCell	primary_visual_cortex-Non-neuronal-pericyte_cell-Peri\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CYSLTR2 LAMA2 NR1H3 MSN PHLDB2	5.59e-05	155	117	5	d8b5145258f075b15080f8739f537f48dd22225e
ToppCell	Substantia_nigra-Macroglia-POLYDENDROCYTE-P1-P1_2-Tnr\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	MATN1 PABPC1 BRCA1 KIF19	5.90e-05	80	117	4	0d02b242164d27f38f70ed77b106612fc7a3abca
ToppCell	Substantia_nigra-Macroglia-POLYDENDROCYTE-P1-P1_2\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	MATN1 PABPC1 BRCA1 KIF19	5.90e-05	80	117	4	313344cf7309bc17ca131b92a91b24489df577e2
ToppCell	Substantia_nigra-Macroglia-POLYDENDROCYTE-P1-P1_2-Tnr-Polydendrocyte.Tnr.Tmem2_(Tmem2)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	MATN1 PABPC1 BRCA1 KIF19	5.90e-05	80	117	4	b95e4456adb7f7d42825351f010376c10bb35380
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_artery-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	USP26 BMX EFNB2 ST8SIA6 SLCO2A1	5.94e-05	157	117	5	275a4c6fef1fff8da2bdc48e3924ad05c5e5cfc8
Drug	N-methylmesoporphyrin	COL3A1 MATN1 PTCH1 MMP2 MMUT	2.02e-06	42	113	5	CID000444708
Drug	KU55933	KAT5 KAT7 BRCA1 CLTC NPAT	3.98e-06	48	113	5	CID005278396
Disease	Malignant neoplasm of breast	NAT2 DPYD FRMPD1 TP53I3 LAMA2 PABPC1 EDNRB PER3 BRCA1 BRCA2 SYNE2 MTR UMPS MMP2 OCLN KIT EIF3M	8.16e-07	1074	114	17	C0006142
Disease	Mammary Carcinoma, Human	NAT2 DPYD PABPC1 EDNRB PER3 BRCA1 BRCA2 MTR UMPS MMP2 OCLN KIT	9.48e-07	525	114	12	C4704874
Disease	Mammary Neoplasms, Human	NAT2 DPYD PABPC1 EDNRB PER3 BRCA1 BRCA2 MTR UMPS MMP2 OCLN KIT	9.48e-07	525	114	12	C1257931
Disease	Mammary Neoplasms	NAT2 DPYD PABPC1 EDNRB PER3 BRCA1 BRCA2 MTR UMPS MMP2 OCLN KIT	9.86e-07	527	114	12	C1458155
Disease	Breast Carcinoma	NAT2 DPYD PABPC1 EDNRB PER3 BRCA1 BRCA2 MTR UMPS MMP2 OCLN KIT	1.22e-06	538	114	12	C0678222
Disease	ductal carcinoma in situ (biomarker_via_orthology)	BRCA1 BRCA2	1.48e-05	2	114	2	DOID:0060074 (biomarker_via_orthology)
Disease	Hereditary site-specific ovarian cancer syndrome	BRCA1 BRCA2	1.48e-05	2	114	2	C4749652
Disease	esophagus squamous cell carcinoma (is_implicated_in)	PTPRT EFNB2 BRCA1 BRCA2	2.79e-05	45	114	4	DOID:3748 (is_implicated_in)
Disease	unipolar depression, bipolar disorder	NOL4 PCLO SPPL3 GRM5 SYNE2 RAB27B	3.30e-05	156	114	6	EFO_0003761, MONDO_0004985
Disease	Pancreatic Neoplasm	DPYD PTCH1 BRCA1 BRCA2 MMP2	4.43e-05	100	114	5	C0030297
Disease	Malignant neoplasm of pancreas	DPYD PTCH1 BRCA1 BRCA2 MMP2	4.87e-05	102	114	5	C0346647
Disease	pancreatic cancer (is_implicated_in)	NAT2 DPYD BRCA1 BRCA2 MTR	7.61e-05	112	114	5	DOID:1793 (is_implicated_in)
Disease	Hereditary breast ovarian cancer syndrome	BRCA1 BRCA2	8.83e-05	4	114	2	cv:C0677776
Disease	Noonan syndrome (implicated_via_orthology)	LZTR1 APAF1	8.83e-05	4	114	2	DOID:3490 (implicated_via_orthology)
Disease	hereditary breast ovarian cancer syndrome (is_implicated_in)	BRCA1 BRCA2	1.47e-04	5	114	2	DOID:5683 (is_implicated_in)
Disease	triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement	NAT2 KAT5 PABPC4 NR1H3 APOB SYNE2	1.53e-04	206	114	6	EFO_0004612, EFO_0020947
Disease	Schizophrenia	COL3A1 DPYD LAMA2 GRIA2 GC GRM5 SBNO2 EFNB2 FSTL1 BRCA1 TET1 MTR	1.62e-04	883	114	12	C0036341
Disease	Liver Cirrhosis, Experimental	COL3A1 EZR GNPDA1 ZFYVE16 RBL2 APAF1 GC PFKP MSN FSTL1 MMP2	2.09e-04	774	114	11	C0023893
Disease	Congenital muscular dystrophy (disorder)	LAMA2 SYNE2	2.20e-04	6	114	2	C0699743
Disease	Usher Syndrome, Type I	CIB2 PCDH15	2.20e-04	6	114	2	C1568247
Disease	Adult only	BRCA1 BRCA2	2.20e-04	6	114	2	C3842001
Disease	Malignant neoplasm of urinary bladder	NAT2 LAMA2 PABPC1 BRCA2 MMP2	2.24e-04	141	114	5	C0005684
Disease	triglyceride measurement, phospholipid measurement	NAT2 KAT5 PABPC4 NR1H3 APOB	2.64e-04	146	114	5	EFO_0004530, EFO_0004639
Disease	Drug toxicity	NAT2 GC SLCO2A1 MTR	3.21e-04	84	114	4	C0013221
Disease	Adverse reaction to drug	NAT2 GC SLCO2A1 MTR	3.21e-04	84	114	4	C0041755
Disease	retinal detachment, retinal break	FRAS1 LAMA2 GRM5	3.36e-04	35	114	3	EFO_0005773, EFO_0010698
Disease	Pancreatic carcinoma, familial	BRCA1 BRCA2	5.23e-04	9	114	2	C2931038
Disease	pancreatic cancer (is_marker_for)	DPYD APAF1 PTCH1 MMP2	6.47e-04	101	114	4	DOID:1793 (is_marker_for)
Disease	Fanconi anemia (is_implicated_in)	BRCA1 BRCA2	6.52e-04	10	114	2	DOID:13636 (is_implicated_in)
Disease	type 2 diabetes mellitus (implicated_via_orthology)	AFF2 EDNRB LNPEP MTR	7.48e-04	105	114	4	DOID:9352 (implicated_via_orthology)
Disease	C-reactive protein measurement	NAT2 DPYD PIGL KAT5 PABPC4 SPPL3 APOB GRM5 IL18RAP CYFIP2 AACS PCDH15 KIT	7.88e-04	1206	114	13	EFO_0004458
Disease	Leukoencephalopathy	DPYD MTR	7.95e-04	11	114	2	C0270612
Disease	complement C1q tumor necrosis factor-related protein 5 measurement	APAF1 LNPEP	7.95e-04	11	114	2	EFO_0801494
Disease	Aortic Valve Insufficiency	COL3A1 FSTL1	7.95e-04	11	114	2	C0003504
Disease	Gastrointestinal Stromal Sarcoma	PTCH1 IFT52 KIT	8.05e-04	47	114	3	C3179349
Disease	triglyceride measurement, intermediate density lipoprotein measurement	NAT2 APOB BRCA2 SYNE2	9.21e-04	111	114	4	EFO_0004530, EFO_0008595
Disease	Gastrointestinal Stromal Tumors	PTCH1 IFT52 KIT	9.64e-04	50	114	3	C0238198
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	NAT2 KAT5 NR1H3 APOB SYNE2	1.10e-03	200	114	5	EFO_0004611, EFO_0020945
Disease	Benign tumor of pancreas	BRCA1 BRCA2	1.12e-03	13	114	2	C0347284
Disease	acute lymphoblastic leukemia (is_implicated_in)	NAT2 DPYD MTR	1.27e-03	55	114	3	DOID:9952 (is_implicated_in)
Disease	Metabolic Bone Disorder	GC MMP2	1.31e-03	14	114	2	C0005944
Disease	Childhood Ataxia with Central Nervous System Hypomyelinization	DPYD MTR	1.31e-03	14	114	2	C1858991
Disease	Diabetic Neuralgia	GRM5 MMP2	1.31e-03	14	114	2	C0751074
Disease	Diabetic Neuropathies	GRM5 MMP2	1.31e-03	14	114	2	C0011882
Disease	Asymmetric Diabetic Proximal Motor Neuropathy	GRM5 MMP2	1.31e-03	14	114	2	C0271674
Disease	Symmetric Diabetic Proximal Motor Neuropathy	GRM5 MMP2	1.31e-03	14	114	2	C0271673
Disease	Diabetic Mononeuropathy	GRM5 MMP2	1.31e-03	14	114	2	C0271678
Disease	Diabetic Autonomic Neuropathy	GRM5 MMP2	1.31e-03	14	114	2	C0271686
Disease	Diabetic Amyotrophy	GRM5 MMP2	1.31e-03	14	114	2	C0271685
Disease	Diabetic Polyneuropathies	GRM5 MMP2	1.31e-03	14	114	2	C0271680
Disease	Diabetic Asymmetric Polyneuropathy	GRM5 MMP2	1.31e-03	14	114	2	C0393835
Disease	Testicular Germ Cell Tumor	MMP2 KIT	1.31e-03	14	114	2	C1336708
Disease	Hereditary Breast and Ovarian Cancer Syndrome	BRCA1 BRCA2	1.31e-03	14	114	2	C0677776
Disease	ovarian cancer (is_implicated_in)	APOB BRCA1 BRCA2	1.34e-03	56	114	3	DOID:2394 (is_implicated_in)
Disease	triglycerides in LDL measurement	NAT2 APOB SYNE2	1.34e-03	56	114	3	EFO_0022320
Disease	hair color	EZR FRAS1 ZFYVE16 GRM5 EDNRB SYNE2	1.34e-03	311	114	6	EFO_0003924
Disease	depressive symptom measurement	NOL4 PCLO SPPL3 PTCH1 GRM5 SYNE2 RAB27B	1.36e-03	426	114	7	EFO_0007006
Disease	platelet storage pool deficiency (implicated_via_orthology)	RAB27A RAB27B	1.50e-03	15	114	2	DOID:2223 (implicated_via_orthology)
Disease	Osteopenia	GC MMP2	1.50e-03	15	114	2	C0029453
Disease	triglycerides:total lipids ratio, intermediate density lipoprotein measurement	NAT2 KAT5 APOB SYNE2	1.52e-03	127	114	4	EFO_0008595, EFO_0020947
Disease	triglycerides to total lipids in small LDL percentage	NAT2 KAT5 APOB	1.56e-03	59	114	3	EFO_0022337
Disease	Malignant Neoplasms	DPYD BRCA1 OCLN KIT	1.56e-03	128	114	4	C0006826
Disease	Neuralgia, Supraorbital	GRM5 SCN10A	1.71e-03	16	114	2	C0038870
Disease	Neuralgia	GRM5 SCN10A	1.71e-03	16	114	2	C0027796
Disease	Schizoaffective disorder-bipolar type	PCLO PTCH1	1.71e-03	16	114	2	EFO_0009965
Disease	Neuralgia, Atypical	GRM5 SCN10A	1.71e-03	16	114	2	C0234247
Disease	Neuralgia, Stump	GRM5 SCN10A	1.71e-03	16	114	2	C0234249
Disease	myopia (is_implicated_in)	LAMA2 MMP2	1.71e-03	16	114	2	DOID:11830 (is_implicated_in)
Disease	Neuralgia, Iliohypogastric Nerve	GRM5 SCN10A	1.71e-03	16	114	2	C0423712
Disease	Neuralgia, Perineal	GRM5 SCN10A	1.71e-03	16	114	2	C0423711
Disease	Paroxysmal Nerve Pain	GRM5 SCN10A	1.71e-03	16	114	2	C0751373
Disease	Nerve Pain	GRM5 SCN10A	1.71e-03	16	114	2	C0751372
Disease	Neuralgia, Ilioinguinal	GRM5 SCN10A	1.71e-03	16	114	2	C0751371
Disease	Neuralgia, Vidian	GRM5 SCN10A	1.71e-03	16	114	2	C0042656
Disease	Intellectual Disability	PTPN23 GRIA2 ZNF462 ERLIN2 SHANK2 BRCA1 UMPS	1.79e-03	447	114	7	C3714756
Disease	level of Sphingomyelin (d32:1) in blood serum	RABEP1 SYNE2	1.94e-03	17	114	2	OBA_2045173
Disease	serum alanine aminotransferase measurement	EZR PDS5B PCLO APOB PTCH1 CYFIP2 ZC3H7A TET1 CARS2 SOS2	2.02e-03	869	114	10	EFO_0004735
Disease	Bladder Neoplasm	NAT2 LAMA2 PABPC1 MMP2	2.16e-03	140	114	4	C0005695
Disease	stomach cancer (is_marker_for)	LZTR1 PTCH1 EFNB2 BRCA1	2.28e-03	142	114	4	DOID:10534 (is_marker_for)
Disease	Noonan-Like Syndrome With Loose Anagen Hair	LZTR1 SOS2	2.42e-03	19	114	2	C3501846
Disease	Hydrops Fetalis	LZTR1 SOS2	2.42e-03	19	114	2	C0020305
Disease	Pancreatic carcinoma	BRCA1 BRCA2	2.42e-03	19	114	2	C0235974
Disease	Noonan syndrome-like disorder with loose anagen hair	LZTR1 SOS2	2.42e-03	19	114	2	C1843181
Disease	Cardio-facio-cutaneous syndrome	LZTR1 SOS2	2.42e-03	19	114	2	C1275081
Disease	Costello syndrome (disorder)	LZTR1 SOS2	2.42e-03	19	114	2	C0587248
Disease	triglycerides to total lipids in very small VLDL percentage	NAT2 KAT5 APOB	2.44e-03	69	114	3	EFO_0022341
Disease	Bipolar Disorder	PCLO GRIA2 GRM5 SHANK2 PER3 BRCA2 MTR	2.57e-03	477	114	7	C0005586
Disease	Cleft palate	PTCH1 VIRMA PHEX	2.65e-03	71	114	3	HP_0000175
Disease	Adenocarcinoma of prostate	BRCA1 BRCA2	2.69e-03	20	114	2	C0007112
Disease	triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement	NAT2 KAT5 APOB SYNE2	2.78e-03	150	114	4	EFO_0004611, EFO_0020947
Disease	BREAST CANCER	BRCA1 BRCA2	2.96e-03	21	114	2	114480
Disease	esophagus squamous cell carcinoma (is_marker_for)	PTCH1 EFNB2 MMP2	2.98e-03	74	114	3	DOID:3748 (is_marker_for)
Disease	response to alcohol	LAMA2 SHANK2 PCDH15	3.10e-03	75	114	3	EFO_0005526
Disease	free cholesterol to total lipids in small VLDL percentage	NAT2 KAT5 APOB	3.10e-03	75	114	3	EFO_0022287
Disease	Mammary Neoplasms, Experimental	EZR BRCA1 LNPEP MMP2	3.12e-03	155	114	4	C0024668
Disease	Craniofacial Abnormalities	APAF1 PTCH1 PHEX MMP2	3.20e-03	156	114	4	C0376634
Disease	Paroxysmal atrial fibrillation	ZNF462 SYNE2 SCN10A PHLDB2	3.20e-03	156	114	4	C0235480
Disease	familial atrial fibrillation	ZNF462 SYNE2 SCN10A PHLDB2	3.20e-03	156	114	4	C3468561
Disease	Persistent atrial fibrillation	ZNF462 SYNE2 SCN10A PHLDB2	3.20e-03	156	114	4	C2585653
Disease	mucocutaneous lymph node syndrome	COL3A1 SHANK2 TPD52	3.22e-03	76	114	3	EFO_0004246

Protein segments in the cluster

Peptide	Gene	Start	Entry
AKFDGAQEKFNTYVT	UNC13A	11	Q9UPW8
YFKSGKYSTFRLSDN	USP26	41	Q9BXU7
LKKDNDSYVSFYNAL	APAF1	61	O14727
EKYVFAVAAYSNNGK	CFAP54	981	Q96N23
YEFEKDLSKQLGFFS	CCDC116	451	Q8IYX3
DENGNKYRKAYFSKF	AACS	501	Q86V21
YDSNSKKIYGSQPNF	BMX	216	P51813
ADALFEKFGKAVNYA	AFF2	1086	P51816
IDGYNAQYNASKKSL	ADPRM	76	Q3LIE5
NKNYYGAAKMIFSDN	DPYD	106	Q12882
LKFKANDHGYDNFRS	EDNRB	421	P24530
ADGKYAQKLFNDLFE	CHRNA9	26	Q9UGM1
TEGQFQVFAKTAYYK	NPR1	546	P16066
AQYKKAFSAVDTDGN	CALML5	11	Q9NZT1
KPKQSYYFAGFQDDS	ATG4C	326	Q96DT6
GDDNYLALKNSQGKY	ADAMTS15	721	Q8TE58
FFKGAYYLKLENQSL	MMP2	631	P08253
LYQYTDGKFNSKFIT	RAB27A	26	P51159
GKTTFLYRYTDNKFN	RAB27B	21	O00194
YKKYALQSAAGKDAA	PDS5B	416	Q9NTI5
AAAGFNYKKEDFSEA	TP53I3	186	Q53FA7
ALGYNYKAKSAGNLD	RABEP1	421	Q15276
LYKRNFDTGLQEYKS	OCLN	431	Q16625
GGKYNSAKKDNDFIY	PTPN23	306	Q9H3S7
DNKALYDTFSAFGNI	PABPC1	111	P11940
FFYNAIKSYKTEGRA	SLC25A32	101	Q9H2D1
LKDFSYNREDFAKAG	NR1H3	316	Q13133
QALFDLFDYGKTKNN	NPAT	326	Q14207
NFGESFKAINKAYEE	RBL2	326	Q08999
DNKALYDTFSAFGNI	PABPC4	111	Q13310
TLGDKKDFDAFVSYA	IL18RAP	401	O95256
LIGYFSKEKNSFLNY	KAT7	456	O95251
SFKYTSYNVSEKAGS	FRAS1	2556	Q86XX4
YKIYSNAGEQSFDKL	GRM5	246	P41594
NKYYADSVKGRFTIS	IGHV3-30-5	76	P0DP03
YFYTADFKTINQIGK	MATN1	431	P21941
YTGDIYSNSNLKNKN	LZTR1	136	Q8N653
YSNSNLKNKNDLFEY	LZTR1	141	Q8N653
YKNGDLSFKYVKTFN	GNPDA1	56	P46926
CKAYNDVGKTSAYFN	KIT	491	P10721
SNGKREIYFNSFFKD	NLRP11	301	P59045
NKYYADSVKGRFTIS	IGHV3-30-3	76	P0DP02
SDAQYQFTGIKKYFN	ATP5MK	6	Q96IX5
SYVKFYQNNKDFIDS	EIF3M	251	Q7L2H7
FFEIDGRKNKSYSQN	KAT5	301	Q92993
NKEFYYDIKDTNTAF	FSIP2	6436	Q5CZC0
EQDKVFYSAAKNGSL	CCNYL2	331	Q5T2Q4
ADNGGLKAAYNAYKA	ECE2	711	P0DPD6
FQKNKDYYIISTSNG	EFNB2	126	P52799
YAIFGFYDKKSVNTI	GRIA2	86	P42262
FYKSKNAFDYSEGTD	PCLO	3006	Q9Y6V0
KYSYFQGDSTSKQTR	PER3	716	P56645
YSLKITASDGKNYAS	FAT2	636	Q9NYQ8
LAKYKASYDVSDSGQ	PFKP	761	Q01813
KFLDSNIGFAKQYYN	PDE6A	11	P16499
EESQKLGAQFLKYYS	MANSC4	46	A6NHS7
GFSYTDESNEKKYFA	LNPEP	276	Q9UIQ6
NKKDFYDLAAFITEG	LONP1	916	P36776
ASYAVQSKYGDFNKE	MSN	126	P26038
NNFGLDLKADDKIYF	LAMA2	2456	P24043
NDSAYYALTKFKKQF	CYFIP2	696	Q96F07
DKNGDAYGFYNNSVK	PLBD1	61	Q6P4A8
YKAIASNSKIYFGKD	ERLIN2	286	O94905
YSIYFQALSKANGET	PTPRT	701	O14522
ALSDKGSNKYINYRD	KIF19	286	Q2TAC6
EYKNNKLFLTGESYA	CTSA	166	P10619
SYFKFQVIATDDYGK	PCDH15	1216	Q96QU1
DTGLEYANSYNFAKK	BRCA1	96	P38398
YANSYNFAKKENNSP	BRCA1	101	P38398
GVENQAFYKYAKSSQ	FRMD3	301	A2A2Y4
DNIYSSDKFYKQTVN	APOB	1771	P04114
FNAYKKEIFTTNNGY	IFT52	11	Q9Y366
VYNDSGYLSKNKLDS	BRCA2	1756	P51587
YLENGQTKAFKFEAN	FRMPD1	186	Q5SYB0
YKFKVIAYNSEGKSN	FNDC3A	536	Q9Y2H6
VDKSELKDFFQSYGN	G3BP1	351	Q13283
KGSNYSEILDKYFKN	FSTL1	141	Q12841
KYFKNFDNGDSRLDS	FSTL1	151	Q12841
NGKEAKSQYSLYLNS	CCDC66	176	A2RUB6
NKYYADSVKGRFTIS	IGHV3-30	76	P01768
GFILTYRKFNYKDNT	NAT2	236	P11245
QLAGFDKYKYSAVDT	SELENOI	11	Q9C0D9
NEGEFKAEGNSKFTY	COL3A1	1396	P02461
GSYAVQAKFGDYNKE	EZR	126	P15311
SYFQKAAARGYSKAQ	DELE1	266	Q14154
NKYYADSVKGRFTIS	IGHV3-33	76	P01772
NAKDSFYKSSTQKAY	SPATA48	231	A4D263
YSTAKGNVYFDLKSR	CARS2	186	Q9HA77
GSASEKEFTDYLFNK	SOS2	996	Q07890
ENDTYFKKYNSLLSF	SYNE2	321	Q8WXH0
FSAGNYYNQGETRKK	PIGL	76	Q9Y2B2
GDYNAAKFTKAAKDY	ENTPD4	446	Q9Y227
SGLYFSNLKSKYFAV	MTR	1216	Q99707
NNYKNGSDDGVLAYK	PTCH1	871	Q13635
FSNKTKGYSENDYLQ	ST8SIA6	91	P61647
DLSKYNFENKYGTRA	SBNO2	891	Q9Y2G9
KKYSSSLRFKANGDY	PHLDB2	41	Q86SQ0
GQKRTYKAISESYAF	NOL4	131	O94818
FALGANKDSLSAFEY	SHANK2	501	Q9UPX8
ESNGKAFTDKAYNSQ	TET1	1271	Q8NFU7
LKANYAFKIYDFNTD	CIB2	106	O75838
YDAAKLLYNNVSNFG	CLTC	1211	Q00610
YFAGENFKDRLKSAL	CYSLTR2	306	Q9NS75
KFLEKQYGTSAAYAN	SLCO2A1	351	Q92959
DNDFKSEGKYSKVYA	TSGA13	181	Q96PP4
AFDAGQKKTFLSAEY	SCN10A	586	Q9Y5Y9
KQDIFSFLYGKNYSQ	SPDYE4	176	A6NLX3
FVLRYDNYKKQASGD	SPPL3	281	Q8TCT6
LQTAADAFYKAKNEF	VPS16	651	Q9H269
SQYAAYGEKKSRLSN	GC	221	P02774
YDVQAFKFGDFVLKS	UMPS	16	P11172
DLKAIKFSEADYFGN	PHEX	491	P78562
KKFLDPNNYSANYTE	PXK	116	Q7Z7A4
VKGSYGFEAEFNKSQ	TRAV3	76	A0A0B4J244
YLSDSDFQDIFGKSK	VILL	821	O15195
NDNDFGKYSFLFKDL	ZC3H7A	956	Q8IWR0
LLSKQKYADGAFADF	ZNF462	1931	Q96JM2
FDFDAGVNKSYLYLS	TPD52	16	P55327
ALGDSKSKKSVAYNY	VIRMA	836	Q69YN4
SYDYNENGSNFSKKS	ZNF248	351	Q8NDW4
YYKDNSKAETSNTDF	ZBBX	466	A8MT70
SDSYNYSGTENLKDK	ZFYVE16	216	Q7Z3T8
AGFSTVEESNKFYKD	MMUT	111	P22033